Platelet rich plasma versus placebo for the management of Achilles tendinopathy: protocol for the UK study of Achilles tendinopathy management (ATM) multi-centre randomised trial

INTRODUCTION: In the UK, 150 000 people every year experience mid-substance Achilles tendinopathy. Typically patients are offered a range of treatment options such as exercise, electrotherapy, injections and surgery. With large variations in current practice, there is a pressing need to establish wh...

Descripción completa

Detalles Bibliográficos
Autores principales: Kearney, Rebecca Samantha, Parsons, Nicholas, Ji, Chen, Warwick, Jane, Brown, Jaclyn, Young, Jonathan, Costa, Matthew L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7044811/
https://www.ncbi.nlm.nih.gov/pubmed/32051317
http://dx.doi.org/10.1136/bmjopen-2019-034076
_version_ 1783501644450758656
author Kearney, Rebecca Samantha
Parsons, Nicholas
Ji, Chen
Warwick, Jane
Brown, Jaclyn
Young, Jonathan
Costa, Matthew L
author_facet Kearney, Rebecca Samantha
Parsons, Nicholas
Ji, Chen
Warwick, Jane
Brown, Jaclyn
Young, Jonathan
Costa, Matthew L
author_sort Kearney, Rebecca Samantha
collection PubMed
description INTRODUCTION: In the UK, 150 000 people every year experience mid-substance Achilles tendinopathy. Typically patients are offered a range of treatment options such as exercise, electrotherapy, injections and surgery. With large variations in current practice, there is a pressing need to establish which treatments are effective and which are not. This is the protocol for a multi-centre randomised trial of platelet rich plasma (PRP) versus placebo injection for patients with Achilles tendinopathy. METHODS AND ANALYSIS: Adult patients with mid-substance Achilles tendinopathy for longer than 3 months will be screened. Randomisation will be on a 1:1 basis, stratified by centre and bilateral presentation. Participants will be allocated to either a single PRP injection or placebo injection. A minimum of 240 patients will be recruited into the study; this number will provide 90% power to detect a difference of 12 points in Victorian Institute of Sport Assessment-Achilles score at 6 months. Quality of life, pain and complications data will be collected at baseline, 2-week, 3-month and 6-month post-randomisation. The differences between treatment groups will be assessed on an intention-to-treat basis. ETHICS, REGISTRATION AND DISSEMINATION: This trial was funded by Versus Arthritis and commenced on 1 September 2015 (Versus Arthritis 20831). National Research Ethic Committee approved this study on 30 October 2015 (15/WM/0359). It was registered on the International Standard Randomised Controlled Trial Number (ISRCTN) registry with reference number ISRCTN 13254422 on 28 October 2015. The first site opened to recruitment on 27 April 2016 and the trial was in active recruitment at the point of submitting the protocol paper. The results of this trial will be submitted to a peer-reviewed journal and will inform clinical practice with regard to the treatment of Achilles tendinopathy.
format Online
Article
Text
id pubmed-7044811
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-70448112020-03-09 Platelet rich plasma versus placebo for the management of Achilles tendinopathy: protocol for the UK study of Achilles tendinopathy management (ATM) multi-centre randomised trial Kearney, Rebecca Samantha Parsons, Nicholas Ji, Chen Warwick, Jane Brown, Jaclyn Young, Jonathan Costa, Matthew L BMJ Open Rehabilitation Medicine INTRODUCTION: In the UK, 150 000 people every year experience mid-substance Achilles tendinopathy. Typically patients are offered a range of treatment options such as exercise, electrotherapy, injections and surgery. With large variations in current practice, there is a pressing need to establish which treatments are effective and which are not. This is the protocol for a multi-centre randomised trial of platelet rich plasma (PRP) versus placebo injection for patients with Achilles tendinopathy. METHODS AND ANALYSIS: Adult patients with mid-substance Achilles tendinopathy for longer than 3 months will be screened. Randomisation will be on a 1:1 basis, stratified by centre and bilateral presentation. Participants will be allocated to either a single PRP injection or placebo injection. A minimum of 240 patients will be recruited into the study; this number will provide 90% power to detect a difference of 12 points in Victorian Institute of Sport Assessment-Achilles score at 6 months. Quality of life, pain and complications data will be collected at baseline, 2-week, 3-month and 6-month post-randomisation. The differences between treatment groups will be assessed on an intention-to-treat basis. ETHICS, REGISTRATION AND DISSEMINATION: This trial was funded by Versus Arthritis and commenced on 1 September 2015 (Versus Arthritis 20831). National Research Ethic Committee approved this study on 30 October 2015 (15/WM/0359). It was registered on the International Standard Randomised Controlled Trial Number (ISRCTN) registry with reference number ISRCTN 13254422 on 28 October 2015. The first site opened to recruitment on 27 April 2016 and the trial was in active recruitment at the point of submitting the protocol paper. The results of this trial will be submitted to a peer-reviewed journal and will inform clinical practice with regard to the treatment of Achilles tendinopathy. BMJ Publishing Group 2020-02-12 /pmc/articles/PMC7044811/ /pubmed/32051317 http://dx.doi.org/10.1136/bmjopen-2019-034076 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.
spellingShingle Rehabilitation Medicine
Kearney, Rebecca Samantha
Parsons, Nicholas
Ji, Chen
Warwick, Jane
Brown, Jaclyn
Young, Jonathan
Costa, Matthew L
Platelet rich plasma versus placebo for the management of Achilles tendinopathy: protocol for the UK study of Achilles tendinopathy management (ATM) multi-centre randomised trial
title Platelet rich plasma versus placebo for the management of Achilles tendinopathy: protocol for the UK study of Achilles tendinopathy management (ATM) multi-centre randomised trial
title_full Platelet rich plasma versus placebo for the management of Achilles tendinopathy: protocol for the UK study of Achilles tendinopathy management (ATM) multi-centre randomised trial
title_fullStr Platelet rich plasma versus placebo for the management of Achilles tendinopathy: protocol for the UK study of Achilles tendinopathy management (ATM) multi-centre randomised trial
title_full_unstemmed Platelet rich plasma versus placebo for the management of Achilles tendinopathy: protocol for the UK study of Achilles tendinopathy management (ATM) multi-centre randomised trial
title_short Platelet rich plasma versus placebo for the management of Achilles tendinopathy: protocol for the UK study of Achilles tendinopathy management (ATM) multi-centre randomised trial
title_sort platelet rich plasma versus placebo for the management of achilles tendinopathy: protocol for the uk study of achilles tendinopathy management (atm) multi-centre randomised trial
topic Rehabilitation Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7044811/
https://www.ncbi.nlm.nih.gov/pubmed/32051317
http://dx.doi.org/10.1136/bmjopen-2019-034076
work_keys_str_mv AT kearneyrebeccasamantha plateletrichplasmaversusplaceboforthemanagementofachillestendinopathyprotocolfortheukstudyofachillestendinopathymanagementatmmulticentrerandomisedtrial
AT parsonsnicholas plateletrichplasmaversusplaceboforthemanagementofachillestendinopathyprotocolfortheukstudyofachillestendinopathymanagementatmmulticentrerandomisedtrial
AT jichen plateletrichplasmaversusplaceboforthemanagementofachillestendinopathyprotocolfortheukstudyofachillestendinopathymanagementatmmulticentrerandomisedtrial
AT warwickjane plateletrichplasmaversusplaceboforthemanagementofachillestendinopathyprotocolfortheukstudyofachillestendinopathymanagementatmmulticentrerandomisedtrial
AT brownjaclyn plateletrichplasmaversusplaceboforthemanagementofachillestendinopathyprotocolfortheukstudyofachillestendinopathymanagementatmmulticentrerandomisedtrial
AT youngjonathan plateletrichplasmaversusplaceboforthemanagementofachillestendinopathyprotocolfortheukstudyofachillestendinopathymanagementatmmulticentrerandomisedtrial
AT costamatthewl plateletrichplasmaversusplaceboforthemanagementofachillestendinopathyprotocolfortheukstudyofachillestendinopathymanagementatmmulticentrerandomisedtrial